What the Grant Actually Funded

I. Two numbers

In a laboratory in Wuhan, a group of mice was infected with a bat coronavirus called WIV1. Two weeks later, five of the seven were still alive — a survival rate of 71 percent.

A second group of mice was infected with a virus that did not exist in nature. Scientists had taken the WIV1 backbone and swapped in the spike protein of a different bat coronavirus, SHC014, building a chimera they labeled rWIV1-SHC014 S. Two weeks later, only two of eight of those mice survived — 25 percent.

Both numbers come from the same document: the fifth-year progress report of a grant funded by the U.S. National Institutes of Health, written by the grantee and now public. In the report’s own words, “the pathogenicity of SHC014 is higher than other tested bat SARSr-CoVs in transgenic mice that express hACE2.”¹

This is what it looks like to read a grant from its own paperwork. Not from a press release, not from a critic, not from a headline — from the report the scientists filed with their funder.

II. The grant

The grant was R01AI110964, “Understanding the Risk of Bat Coronavirus Emergence.” Its money originated at the National Institute of Allergy and Infectious Diseases — the institute Dr. Anthony Fauci directed — flowed through the New York nonprofit EcoHealth Alliance, and reached, as a subaward, the Wuhan Institute of Virology.²

Its stated purpose was defensive: to understand how bat coronaviruses might spill over into people, so the world could prepare. The progress report lays out three aims — surveying bats for novel coronaviruses, modeling which ones might be able to infect humans, and then testing those predictions.² It is the third aim that matters here.

III. What Aim 3 did

Under the heading “Specific Aim 3: Testing Predictions of CoV Inter-Species Transmission,” the report describes the experiment plainly. Scientists “continued with in vivo infection experiments of diverse bat SARSr-CoVs on transgenic mice expressing human ACE2” — mice engineered to carry the human receptor the virus uses to enter cells. The mice were infected with four viruses: “the full-length recombinant virus of SARSr-CoV WIV1 and three chimeric viruses with the backbone of WIV1 and S proteins of SHC014, WIV16 and Rs4231, respectively.”¹

In plainer language — the report’s own — the team explained what that meant:

“We used the genetic codes of some of the other viruses we found in bats and inserted the spike protein genes of those viruses (the proteins that attach to cells) into the cultured viruses… We also showed that some of these viruses cause SARS-like illness in mice that are adapted to have similar cell surface receptors to people.”³

Read that twice, because it is the entire story in two sentences. The grant took the genetic backbone of one bat coronavirus, inserted the spike genes of others to create viruses that do not occur in nature, and infected humanized mice to see what would happen. What happened, in some cases, was “SARS-like illness.”

IV. The result

The report records the outcome with clinical precision. “All of the 4 SARSr-CoVs caused lethal infection in hACE2 transgenic mice,” it states, “but the mortality rate vary among 4 groups.” The chimera carrying the SHC014 spike was the deadliest: where 71 percent of the WIV1-infected mice survived, only 25 percent of the rWIV1-SHC014 mice did.¹

It went further. The SHC014 chimera was the only one of the four detectable in the animals’ brains at every time point, “showed an increasing viral titer after infection,” and produced lung lesions “more significant” than the others. From this the authors drew their conclusion about SHC014’s higher pathogenicity.¹

The report describes a parallel line of work with MERS — building “the full-length infectious clone of MERS-CoV” and replacing its receptor-binding domain with those of bat coronaviruses, then showing the resulting chimeras “were able to infect human cells.”¹ The pattern is the same: take a known virus, swap in genetic parts from others, test what the new construct can do.

V. October 2021: the NIH’s own letter

For more than a year, NIH leaders told the public and Congress that the agency had not funded dangerous coronavirus research in Wuhan. Then, on October 20, 2021, the NIH’s principal deputy director, Lawrence Tabak, wrote to Representative James Comer and conceded the central fact.

A “limited experiment” had been conducted, Tabak wrote, to test whether bat coronaviruses “circulating in China were capable of binding to the human ACE2 receptor in a mouse model.” And in that experiment, “laboratory mice infected with the SHC014 WIV1 bat coronavirus became sicker than those infected with the WIV1 bat coronavirus.”⁴ It was the same result the grant’s own report had recorded — now in the NIH’s own hand.

Tabak’s letter also disclosed a compliance failure. The grant carried, he wrote, “a requirement that the grantee report immediately a one log increase in growth” — a tripwire meant to trigger additional review if an experiment made a virus grow more dangerously than expected. EcoHealth, the NIH said, had not reported the result on time.⁵ A congressional oversight report would later make EcoHealth’s reporting failures a central finding.⁶

VI. The word that started a war

Was this “gain-of-function research”? That single phrase has carried years of argument, and the honest answer is that it remains contested — a fact this article will not paper over.

The NIH’s position, in Tabak’s letter, was that the work “was not subject to departmental review under the HHS P3CO Framework” — the federal process for research “reasonably anticipated” to enhance a potential pandemic pathogen — but that, “out of an abundance of caution,” the grant terms had nonetheless included the reporting tripwire that was missed.⁵ Critics read the same facts the other way: a federally funded experiment had made a bat coronavirus more lethal to humanized mice, which is, in plain English, an enhancement of function, whatever the regulatory definition.

We do not adjudicate the label. We report that the experiment happened, that it produced the result described, and that the people responsible for overseeing it disagree, to this day, about what to call it. The reader can hold the grant’s data and the regulatory definition side by side:

VII. What this establishes — and what it does not

Because this subject has been stretched in every direction, the boundaries must be explicit.

The record establishes:

• That an NIH grant, originating at Fauci’s institute, funded the construction of chimeric bat coronaviruses at the Wuhan Institute of Virology and their testing in humanized mice.¹²
• That one chimera, rWIV1-SHC014, made those mice markedly sicker than the natural virus did — the grantee’s own finding, later confirmed by the NIH.¹⁴
• That the grant required immediate reporting of exactly that kind of result, and that the requirement was not met.⁵⁶

The record does not establish — and we will not imply — that:

• This grant produced SARS-CoV-2. The NIH’s letter is unambiguous: the viruses studied “are not and could not have become SARS-CoV-2,” and are “far too divergent to have been the progenitor.”⁷ The genetics support that statement, and we state it as plainly as the NIH did.
• The “gain-of-function” question is settled. It is not; the regulatory definition and the plain-English description point in different directions, and serious people disagree.
• Anyone intended harm. Surveillance of spillover-risk viruses is a legitimate scientific goal, and the grant was framed as defensive.

The story here is narrower, and sturdier, than “Fauci funded the pandemic.” It is that the United States government funded the creation of more-pathogenic chimeric coronaviruses in a Wuhan lab; that the public was told, for years, a far smaller story; and that the funder’s own oversight tripwire failed.

VIII. Why it matters

In May 2021, pressed by Senator Rand Paul about the Wuhan funding, Fauci told the Senate health committee: “the NIH and NIAID categorically has not funded gain-of-function research to be conducted in the Wuhan Institute of Virology.”⁸ Five months later, his agency wrote to Congress describing an experiment in that institute in which a lab-made coronavirus left humanized mice sicker — and acknowledging that the grant’s safety-reporting requirement had been missed.⁴⁵

Whether those two statements can be reconciled depends entirely on the definition of a single contested phrase. That is precisely the problem. When the public’s understanding of what its government funded turns on a regulatory term of art that the funder itself applies one way and the evidence reads another, the gap is no longer scientific. It is a gap in candor — the same gap, in a different chapter, that this series keeps finding in the record.